1.

Record Nr.

UNINA9910143578003321

Titolo

Pharmacometrics : the science of quantitative pharmacology / / edited by Ene I. Ette, Anoixis Corporation, Paul J. Williams, University of the Pacific and Anoixis Corporation

Pubbl/distr/stampa

Hoboken, New Jersey : , : Wiley-Interscience, , [2007]

©2007

ISBN

1-118-67951-2

1-280-82698-3

9786610826988

0-470-08797-8

0-470-08796-X

Descrizione fisica

1 online resource (1227 p.)

Classificazione

44.38

Disciplina

615.1

615/.1

Soggetti

Pharmacology

Pharmacokinetics

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Note generali

Description based upon print version of record.

Nota di bibliografia

Includes bibliographical references and index.

Nota di contenuto

PHARMACOMETRICS; CONTENTS; CONTRIBUTORS; PREFACE; ACKNOWLEDGMENTS; 1. Pharmacometrics: Impacting Drug Development and Pharmacotherapy; PART I GENERAL PRINCIPLES; 2. General Principles of Programming: Computer and Statistical; 3. Validation of Software for Pharmacometric Analysis; 4. Linear, Generalized Linear, and Nonlinear Mixed Effects Models; 5. Bayesian Hierarchical Modeling with Markov Chain Monte Carlo Methods; 6. Estimating the Dynamics of Drug Regimen Compliance; 7. Graphical Displays for Modeling Population Data; 8. The Epistemology of Pharmacometrics; 9. Data Imputation

PART II POPULATION PHARMACOKINETIC BASIS OF PHARMACOMETRICS10. Population Pharmacokinetic Estimation Methods; 11. Timing and Efficiency in Population Pharmacokinetic/Pharmacodynamic Data Analysis Projects; 12. Designing Population Pharmacokinetic Studies for Efficient Parameter



Estimation; 13. Population Models for Drug Absorption and Enterohepatic Recycling; 14. Pharmacometric Knowledge Discovery from Clinical Trial Data Sets; 15. Resampling Techniques and Their Application to Pharmacometrics; 16. Population Modeling Approach in Bioequivalence Assessment

PART III PHARMACOKINETICS / PHARMACODYNAMICS RELATIONSHIP: BIOMARKERS AND PHARMACOGENOMICS, PK/PD MODELS FOR CONTINUOUS DATA, AND PK/PD MODELS FOR OUTCOMES DATA17. Biomarkers in Drug Development and Pharmacometric Modeling; 18. Analysis of Gene Expression Data; 19. Pharmacogenomics and Pharmacokinetic/Pharmacodynamic Modeling; 20. Empirical Pharmacokinetic/Pharmacodynamic Models; 21. Developing Models of Disease Progression; 22. Mechanistic Pharmacokinetic/Pharmacodynamic Models I; 23. Mechanistic Pharmacokinetic/Pharmacodynamic Models II; 24. PK/PD Analysis of Binary (Logistic) Outcome Data

25. Population Pharmacokinetic/Pharmacodynamic Modeling of Ordered Categorical Longitudinal Data26. Transition Models in Pharmacodynamics; 27. Mixed Effects Modeling Analysis of Count Data; 28. Mixture Modeling with NONMEM V; PART IV CLINICAL TRIAL DESIGNS; 29. Designs for First-Time-in-Human Studies in Nononcology Indications; 30. Design of Phase 1 Studies in Oncology; 31. Design and Analysis of Clinical Exposure: Response Trials; PART V PHARMACOMETRIC KNOWLEDGE CREATION; 32. Pharmacometric/Pharmacodynamic Knowledge Creation: Toward Characterizing an Unexplored Region of the Response Surface

33. Clinical Trial Simulation: Theory34. Modeling and Simulation: Planning and Execution; 35. Clinical Trial Simulation: Efficacy Trials; PART VI PHARMACOMETRIC SERVICE AND COMMUNICATION; 36. Engineering a Pharmacometrics Enterprise; 37. Communicating Pharmacometric Analysis Outcome; PART VII SPECIFIC APPLICATION EXAMPLES; 38. Pharmacometrics Applications in Population Exposure-Response Data for New Drug Development and Evaluation; 39. Pharmacometrics in Pharmacotherapy and Drug Development: Pediatric Application

40. Pharmacometric Methods for Assessing Drug-Induced QT and QTc Prolongations for Non-antiarrhythmic Drugs

Sommario/riassunto

Pharmacometrics is the science of interpreting and describing pharmacology in a quantitative fashion. The pharmaceutical industry is integrating pharmacometrics into its drug development program, but there is a lack of and need for experienced pharmacometricians since fewer and fewer academic programs exist to train them. Pharmacometrics: The Science of Quantitative Pharmacology lays out the science of pharmacometrics and its application to drug development, evaluation, and patient pharmacotherapy, providing a comprehensive set of tools for the training and development of pharmac



2.

Record Nr.

UNINA9910784411803321

Autore

Bamford Sandra C. <1962->

Titolo

Biology unmoored : Melanesian reflections on life and biotechnology / / Sandra Bamford

Pubbl/distr/stampa

Berkeley : , : University of California Press, , 2007

©2007

ISBN

1-282-35837-5

9786612358371

0-520-93947-6

1-4337-0138-3

Descrizione fisica

1 online resource (xiv, 230 pages) : illustrations, maps

Disciplina

305.89/912

Soggetti

Hamtai (Papua New Guinean people) - Ethnobiology

Hamtai (Papua New Guinean people) - Agriculture

Hamtai (Papua New Guinean people) - Psychology

Human body - Social aspects - Papua New Guinea - Gulf Province

Indigenous peoples - Ecology - Papua New Guinea - Gulf Province

Ethnobiology - Papua New Guinea - Gulf Province

Biotechnology

Genetic engineering

Gulf Province (Papua New Guinea) Social life and customs

Lingua di pubblicazione

Inglese

Formato

Materiale a stampa

Livello bibliografico

Monografia

Nota di bibliografia

Includes bibliographical references (p. 191-218) and index.

Nota di contenuto

Introduction: conceptual frameworks -- Cultural landscapes -- Insubstantial identities -- Embodiments of detachment -- (Im) mortal undertakings -- Conceiving global identities -- Conclusion: conceptual displacements.

Sommario/riassunto

Biology Unmoored is an engaging examination of what it means to live in a world that is not structured in terms of biological thinking. Drawing upon three years of ethnographic research in the highlands of Papua New Guinea, Sandra Bamford describes a world in which physiological reproduction is not perceived to ground human kinship or human beings' relationship to the organic world. Bamford also exposes



the ways in which Western ideas about relatedness do depend on a notion of physiological reproduction. Her innovative analysis includes a discussion of the advent of assisted reproductive technologies (ARTs), the mapping of the human genome, cloning, the commodification of biodiversity, and the manufacture and sale of genetically modified organisms (GMOs).